Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Multiple Ascending Dose Study of S-606001 in Healthy Adults
jRCT2071240106Phase 1Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in Pompe disease comparing S-606001 with Placebo (2 arms). Primary endpoints: Safety and tolerability of S-606001, Clinical laboratory evaluations and 3 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
S-606001
03
Conditions
Pompe disease
Beyond the preview
Go deeper on jRCT2071240106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240106.